What one share of Altimmune holds
We obtained pemvidutide as part of the acquisition Spitfire Pharma Inc., in July of 2019. Pemvidutide was designed as a MASH therapeutic based on the understanding that targeting both metabolic and liver-specific effects could lead to an improved and differentiated candidate.
Altimmune’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.73 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.61 |
| Cash and investments | $0.32 |
| Debt | $0.18 |
| Book value | $2.44 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | $24.86 | −$118.91 | $0.26 | −$47.07 | — | $64.74 |
| 2018 | $3.69 | −$15.16 | $0.35 | −$3.70 | — | — |
| 2019 | $0.44 | −$1.60 | $0.00 | −$0.73 | — | $2.97 |
| 2020 | $0.32 | −$1.91 | $0.01 | −$1.35 | — | $6.08 |
| 2021 | $0.11 | −$2.35 | $0.29 | −$2.19 | — | $4.86 |
| 2022 | — | −$1.81 | $0.00 | −$1.34 | — | $3.77 |
| 2023 | $0.01 | −$1.66 | $0.00 | −$1.42 | — | $2.75 |
| 2024 | $0.00 | −$1.34 | — | — | — | $1.71 |
| 2025 | $0.00 | −$1.00 | $0.00 | −$0.77 | — | $2.03 |
Common questions about Altimmune
How much does one share of Altimmune earn?
Over the last 12 months, Altimmune lost $0.73 for each share.
Does Altimmune pay a dividend?
Altimmune didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Altimmune’s book value per share?
Altimmune’s book value is $2.44 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Altimmune have?
Each share of Altimmune has $0.32 of cash and investments and $0.18 of debt, as of June 30, 2026.
What is Altimmune’s free cash flow per share?
−$0.61 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Altimmune bought back shares?
Altimmune’s share count rose about 20300% from 2017 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.